Use of kinase inhibitors to manage tuberculosis and other infectious diseases

Patent metadata

Field	Value
Publication number	US-11517571-B2
Application number	US-202016733060-A
Country	US
Kind code	B2
Filing date	Jan 2, 2020
Priority date	Sep 16, 2015
Publication date	Dec 6, 2022
Grant date	Dec 6, 2022

Abstract

This disclosure relates to the use of kinase inhibitor to treat or prevent infectious diseases such as tuberculosis. In certain embodiments, this disclosure relates to treating or preventing an infectious disease comprising administering an effective amount of a kinase inhibitor or other compound disclosed herein to a subject in need thereof. In certain embodiments, the disclosure relates to methods of treating or preventing tuberculosis comprising administering a kinase inhibitor to a subject in need thereof. In certain embodiments, the subject is diagnosed with Mycobacterium tuberculosis (Mtb) that is resistant to multiple antibiotic agents.

First claim

The invention claimed is:

1. A pharmaceutical product for use in the treatment of tuberculosis in the form of a tablet, capsule, or gel comprising imatinib in an amount of 50 to 400 mg in combination with ethambutol, isoniazid, pyrazinamide, rifabutin, rifampin, rifapentine, amikacin, capreomycin, cycloserine, ethionamide, levofloxacin, moxifloxacin, para-aminosalicylic acid, or streptomycin.

2. The pharmaceutical product of claim 1 wherein imatinib is in the amount of 50 to 100 mg.

3. The pharmaceutical product of claim 1 further comprising a carrier selected from dicalcium phosphate dihydrate, calcium sulfate, lactose, sucrose, mannitol, sorbitol, cellulose, microcrystalline cellulose, kaolin, sodium chloride, dry starch, hydrolyzed starches, pregelatinized starch, silicone dioxide, titanium oxide, magnesium aluminum silicate and a polysaccharide.

4. The pharmaceutical product of claim 1 wherein the tablet comprises an enteric coating.

5. The pharmaceutical product of claim 4 wherein the enteric coating comprises an excipient selected from hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl methyl cellulose acetate succinate, hydroxypropyl methylcellulose phthalate, methylcellulose, ethyl cellulose, cellulose acetate, cellulose acetate phthalate, cellulose acetate trimellitate, and carboxymethylcellulose sodium.

6. A pharmaceutical product for use in the treatment of tuberculosis in the form of a tablet, capsule, or gel comprising imatinib in an amount of 50 to 400 mg in combination with bedaquiline.

7. The pharmaceutical product of claim 6 wherein imatinib is in the amount of 50 to 100 mg.

8. The pharmaceutical product of claim 6 further comprising a carrier selected from dicalcium phosphate dihydrate, calcium sulfate, lactose, sucrose, mannitol, sorbitol, cellulose, microcrystalline cellulose, kaolin, sodium chloride, dry starch, hydrolyzed starch, pregelatinized starch, silicone dioxide, titanium oxide, magnesium aluminum silicate and a polysaccharide.

9. The pharmaceutical product of claim 6 wherein the tablet comprises an enteric coating.

10. The pharmaceutical product of claim 9 wherein the enteric coating comprises an excipient selected from hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl methyl cellulose acetate succinate, hydroxypropyl methylcellulose phthalate, methylcellulose, ethyl cellulose, cellulose acetate, cellulose acetate phthalate, cellulose acetate trimellitate, and carboxymethylcellulose sodium.

11. A pharmaceutical product for use in the treatment of tuberculosis in the form of a tablet, capsule, or gel comprising imatinib in an amount of 50 to 400 mg in combination with delamanid.

12. The pharmaceutical product of claim 11 wherein imatinib is in the amount of 50 to 100 mg.

13. The pharmaceutical product of claim 11 further comprising a carrier selected from dicalcium phosphate dihydrate, calcium sulfate, lactose, sucrose, mannitol, sorbitol, cellulose, microcrystalline cellulose, kaolin, sodium chloride, dry starch, hydrolyzed starch, pregelatinized starch, silicone dioxide, titanium oxide, magnesium aluminum silicate and a polysaccharide.

14. The pharmaceutical product of claim 11 , wherein the tablet comprises an enteric coating.

15. The pharmaceutical product of claim 14 wherein the enteric coating comprises an excipient selected from hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl methyl cellulose acetate succinate, hydroxypropyl methylcellulose phthalate, methylcellulose, ethyl cellulose, cellulose acetate, cellulose acetate phthalate, cellulose acetate trimellitate, and carboxymethylcellulose sodium.

Assignees

• Univ Emory

Inventors

• Kalman Daniel

Classifications

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K31/506 Primary

  not condensed and containing further heterocyclic rings · CPC title

• A61P31/06

  for tuberculosis · CPC title

• A61K2300/00

  Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title